Beyond dopamine: KarXT and emerging mechanism-based therapies in schizophrenia. (PubMed, Front Psychiatry) - Oct 9, 2026 - "While mainstream drugs (e.g. haloperidol, chlorpromazine, risperidone, olanzapine, quetiapine, aripiprazole) mainly antagonize dopamine D2 or serotonin 5-HT2A receptors, KarXT acts through transient activation of muscarinic M1 and M4 receptors. In this narrative review, we discuss in detail the pharmacological mechanism, basis of preclinical development, and clinical outcomes of KarXT. We also contextualize this drug within the development of a new wave of non-D2 antipsychotics, highlighting cholinergic dysfunction as one important mechanistic pathway within the broader multidimensional neurobiology of schizophrenia."
Journal • Review • CNS Disorders • Metabolic Disorders • Psychiatry • Schizophrenia
|
|
Izabela ?uraw; Krystian Urba?ski; Patryk Kogut
|